Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Report: National investment on childhood and adolescent cancer research

The first-ever detailed examination of a country's investment in research on childhood and adolescent cancers was released today by the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (the Partnership).

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

New chromosomal abnormality in acute lymphoblastic leukemia

Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.

19 Oct 2009

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

Managing Myeloma (www.ManagingMyeloma.com), an accredited multi-supported educational website for multidisciplinary professionals, announces the opportunity for fellows in oncology to win a scholarship to attend the December 2009 American Society of Hematology Annual Meeting in New Orleans, Louisiana. The scholarship includes registration fees, airfare, hotel accommodations, and a per diem for meals.

15 Oct 2009

North Bend Medical Centers partners with Oracle and PracticeOne to support its medical specialties

North Bend Medical Centers of Coos Bay, Oregon, a 55-physician, 300+ employee, multi-specialty clinic and provider to over 60,000 patients, is an innovative user of healthcare information technology. The clinic is comprised of five locations across southern Oregon and represents 15 medical specialties and has partnered closely with PracticeOne and Oracle as key technology providers to support its doctors and clinics.

13 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

Bio-Matrix Scientific Group provides updates on COPD research

Bio-Matrix Scientific Group, Inc. provided a progress report on the Company’s previously announced new opportunities. The Company has been moving forward in the areas of stem cell research for treatment of Chronic Obstructive Pulmonary Disease (COPD), Tumor Banking and Cancer Treatment.

12 Oct 2009

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

The American Society of Hematology (ASH) is proud to announce the participants in the 2009 ASH Visitor Training Program, which builds hematologic capacity in developing countries. Through this program, hematologists and medical professionals from developing countries receive valuable clinical, laboratory, or technological training on a specific topic at a host institution under the mentorship of an ASH member anywhere in the world.

12 Oct 2009

NIH awards Beth Israel Deaconess Medical Center $38.2M in grants

Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).

12 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

HST Global, Inc. today announced a strategic R&D alliance with Dr. James W. Forsythe for the research and development of HST’s exclusive Nutraceutical and Medical Food formulation platform.

9 Oct 2009

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

8 Oct 2009

Entest BioMedical applies for Phase II grant from National Cancer Institute

Entest BioMedical, Inc. a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

8 Oct 2009

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

Aflac announced that it has raised more than $1.16 million for the Aflac Cancer Center through a matching grant campaign with Causes on Facebook, making it the largest sponsored campaign in the history of Causes. The effort also resulted in 851,215 new members joining the Aflac Cancer Center Cause, helping to generate awareness and financial support during Childhood Cancer Awareness Month.

8 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

Hematology News and Research

Further Reading

New tools needed to identify men and women at risk for the most aggressive cancers

Report: National investment on childhood and adolescent cancer research

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Article evaluating StemEx therapy for leukemia and lymphoma to be published

IL-2 compound ineffective against HIV-AIDS

New chromosomal abnormality in acute lymphoblastic leukemia

FDA grants marketing approval for Elitek

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

North Bend Medical Centers partners with Oracle and PracticeOne to support its medical specialties

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Bio-Matrix Scientific Group provides updates on COPD research

2009 ASH Visitor Training Program to build hematologic capacity in developing countries

NIH awards Beth Israel Deaconess Medical Center $38.2M in grants

New soy germ-based ingredient improves menopausal symptoms

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia

Entest BioMedical applies for Phase II grant from National Cancer Institute

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

Schering-Plough receives FDA recommendation approval for PEGINTRON

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo